TY - JOUR
T1 - Survey on current practice within the European Low-Grade Glioma Network
T2 - Where do we stand and what is the next step?
AU - Mandonnet, Emmanuel
AU - Wager, Michel
AU - Almairac, Fabien
AU - Baron, Marie Helene
AU - Blonski, Marie
AU - Freyschlag, Christian F.
AU - Barone, Fabio
AU - Fontaine, Denys
AU - Pallud, Johan
AU - Hegi, Monika
AU - Viegas, Catarina
AU - Zetterling, Maria
AU - Spena, Giannantonio
AU - Goodden, John
AU - Rutten, Geert Jan
AU - Taillandier, Luc
AU - Foroglu, Nicolas
AU - Darlix, Amélie
AU - Skrap, Miran
AU - Martino, Juan
AU - von Campe, Gord
AU - Madadaki, Caterina
AU - Gayat, Etienne
AU - de Witt Hamer, Philip
AU - Robles, Santiago Gil
AU - Sarubbo, Silvio
AU - Santorius, Thomas
AU - Bello, Lorenzo
AU - Forster, Marie Therese
AU - Duffau, Hugues
N1 - Publisher Copyright:
© The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Diffuse low-grade glioma form a rare entity affecting young people. Despite advances in surgery, chemotherapy, and radiation therapy, diffuse low-grade glioma are still incurable. According to current guidelines, maximum safe resection, when feasible, is the first line of treatment. Apart from surgery, all other treatment modalities (temozolomide, procarbazine-CCNU-vincristine regimen, and radiation therapy) are handled very differently among different teams, and this in spite of recent results of several phase 3 studies. Based on a European survey, this paper aimed to get a picture of this heterogeneity in diffuse low-grade glioma management, to identify clinically relevant questions raised by this heterogeneity of practice, and to propose new methodological frameworks to address these questions.
AB - Diffuse low-grade glioma form a rare entity affecting young people. Despite advances in surgery, chemotherapy, and radiation therapy, diffuse low-grade glioma are still incurable. According to current guidelines, maximum safe resection, when feasible, is the first line of treatment. Apart from surgery, all other treatment modalities (temozolomide, procarbazine-CCNU-vincristine regimen, and radiation therapy) are handled very differently among different teams, and this in spite of recent results of several phase 3 studies. Based on a European survey, this paper aimed to get a picture of this heterogeneity in diffuse low-grade glioma management, to identify clinically relevant questions raised by this heterogeneity of practice, and to propose new methodological frameworks to address these questions.
KW - Diffuse low-grade glioma
KW - Evidence-based medicine
KW - GLIOCOM
KW - Surgery
KW - Survey
UR - https://www.scopus.com/pages/publications/85039745601
U2 - 10.1093/nop/npw031
DO - 10.1093/nop/npw031
M3 - Article
AN - SCOPUS:85039745601
SN - 2054-2577
VL - 4
SP - 241
EP - 247
JO - Neuro-Oncology Practice
JF - Neuro-Oncology Practice
IS - 4
M1 - npw031
ER -